{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
icosapent ethyl
to a specific field?
Class (Stereo):
CHEMICAL (ABSOLUTE)
Clentiazem is a chloride derivative of diltiazem, originated in Tanabe Seiyaku. It works as a blocker of calcium channels. The drug was investigated in the clinical trials for the treatment of stable angina, and essential hypertension. Despite the positive results of clinical trials, no development of the drug was reported.
Status:
Investigational
Source:
INN:eticyclidine [INN]
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Eticyclidine (N-ethyl-1-phenylcyclohexylamine) is a phencyclidine derivative exerting nearly the same pharmacological profile as the parent compound. In rodents, it induces stereotypy, ataxia, interoceptive effect and hypothermia.
Class (Stereo):
CHEMICAL (UNKNOWN)
Cogazocine is an opioid analgesic of the benzomorphan family, invented by the Dutch company ACF Chemiedfarma N.V. The compound was active in a tail withdrawal and writhing tests in rats and possessed nalorphine-like activity in rats after an intravenous dose of 0.04 mg/kg.
Status:
Investigational
Source:
NCT01064037: Phase 2 Interventional Terminated Heart Failure
(2010)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Conditions:
Cinaciguat acts specifically on oxidized/haem-free soluble guanylyl cyclase by binding to the enzyme's haem pocket and mimicking the nitric-oxide-bound haem group. It is in clinical development for the treatment of acute decompensated heart failure. Cinaciguat had been in phase II clinical trials. However, trials were terminated early because of an excess of hypotension in the cinaciguat arms and subsequent slow enrolment.
Status:
Investigational
Source:
NCT00432575: Phase 2 Interventional Completed Smoking Cessation
(2007)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Surinabant is a cannabinoid receptor type 1 antagonist developed by Sanofi-Aventis for the treatment for nicotine addiction and obesity. In preclinical models, Surinabant reduced body weight gain, as well as plasma glucose levels and triglycerides. Surinabant also reduced insulin and leptin secretion and increased adiponectin and corticosterone levels in rats. Phase I and phase II studies showed good clinical safety profiles in healthy subjects and in obese subjects, although doses higher than 10mg/day were associated with gastrointestinal events and sleep disorders.
Status:
Investigational
Source:
NCT00143611: Phase 3 Interventional Completed Sepsis
(2005)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Resatorvid (TAK-242) is a Toll-like receptor 4 (TLR4) antagonist that was designed for the treatment of severe sepsis because of its inhibitory effect on suppressing cytokine levels. This compound suppresses production of inflammatory mediators by inhibiting signal transduction through TLR4. It has also been shown that topical resatorvid, in a UV-induced skin tumorigenesis model, displays photochemopreventive activity, suppressing tumor area and multiplicity. Resatorvid has furthermore shown neuroprotective effects after traumatic brain injury (in a mouse model). Phase III studies evaluating the effects of resatorvid on sepsis have been completed. One such study was ended after it was determined that there was insufficient cytokine suppression in the first stage of the study.
Status:
Investigational
Source:
NCT00143520: Phase 2/Phase 3 Interventional Completed Type 2 Diabetes
(2004)
Source URL:
Class (Stereo):
CHEMICAL (RACEMIC)
Rivoglitazone hydrochloride (CS-011) is a thiazolidinedione-derivative peroxisome proliferator–activated receptor (PPAR)-γ agonist. It has been developed as potential treatment in type 2 diabetes mellitus and was shown to decrease plasma glucose and triglyceride levels in a dose-dependent manner in animals. Phase II and III clinical studies have assessed the efficacy and safety of rivoglitazone hydrochloride in patients with type 2 diabetes mellitus.
Status:
Investigational
Source:
INN:flutomidate [INN]
Source URL:
Class (Stereo):
CHEMICAL (RACEMIC)
Flutomidate was studied as a hypnotic agent. Information about the current use of this agent is not available.
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Setoperone is and antagonist of the brain serotonin 5-HT2 receptor and particular the 5-HT2A isoform. Setoperone is radiolabeled with the radioisotope fluorine-18 and is used in positron emission tomography (PET) in neuroimaging for the study neuropsychiatric disorders, such as schizophrenia and depression.
Status:
Investigational
Source:
USAN:ROSARAMICIN BUTYRATE [USAN]
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
